Caspofungin

CHEMBL1630575 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1093.3 g/mol

LogP

0.3

Phase

4

An antifungal agent belonging to the echinocandin class that inhibits the synthesis of beta-1,3-D-glucan, an essential component of the fungal cell wall not found in human cells. It is used intravenously to treat invasive Aspergillus and Candida infections in patients who are unresponsive to or intolerant of other antifungals. Its targeted mechanism results in a favorable tolerability profile compared to older antifungals.

Masse moléculaire

1093,3000 g/mol

LogP

0,30

TPSA

412,00 Å²

Règle des 5 de Lipinski

Non conforme

Aires thérapeutiques

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Non-Alcoholic Fatty Liver Disease Obesity Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O

InChI

InChI=1S/C52H88N10O15/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75)/t28-,29+,30+,33+,34-,35-,36+,37-,38+,40-,41-,42-,43-,44-,45-,46-/m0/s1

Molecular Formula

C52H88N10O15

HBD / HBA

16 / 18

Liaisons Rotatives

23

Atomes Lourds

77

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

An antifungal agent belonging to the echinocandin class that inhibits the synthesis of beta-1,3-D-glucan, an essential component of the fungal cell wall not found in human cells. It is used intravenously to treat invasive Aspergillus and Candida infections in patients who are unresponsive to or intolerant of other antifungals. Its targeted mechanism results in a favorable tolerability profile compared to older antifungals.

Yes, Caspofungin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1630575. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 16119814. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Caspofungin sur PillFYI

Structure

Données Clés

Formule: C52H88N10O15
Synonymes: 1

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.